Source-grounded facts extracted from VYNE Therapeutics Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Rachael Alford was appointed as Chief Operating Officer at VYNE Therapeutics Inc..
“the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer, Steven Ryder, M.D. as the Company's Chief Medical Officer, Lori Payton, Ph.D. as the Company's Chief Development Officer and Rachael Alford, Ph.D. as the Company's Chief Operating Officer”
Lori Payton was appointed as Chief Development Officer at VYNE Therapeutics Inc..
“the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer, Steven Ryder, M.D. as the Company's Chief Medical Officer, Lori Payton, Ph.D. as the Company's Chief Development Officer”
Steven Ryder was appointed as Chief Medical Officer at VYNE Therapeutics Inc..
“the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer, Steven Ryder, M.D. as the Company's Chief Medical Officer”
Tyler Zeronda was appointed as Chief Financial Officer at VYNE Therapeutics Inc..
“the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer”
Rebecca Frey was appointed as Chief Executive Officer at VYNE Therapeutics Inc..
“the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer”
Mutya Harsch resigned as Chief Legal Officer and General Counsel at VYNE Therapeutics Inc..
“each of David Domzalski, VYNE’s President and Chief Executive Officer, Iain Stuart, Ph.D., VYNE’s Chief Scientific Officer, and Mutya Harsch, VYNE’s Chief Legal Officer and General Counsel, resigned as executive officers at the Closing and their employment was terminated effective July 27, 2026”
Iain Stuart resigned as Chief Scientific Officer at VYNE Therapeutics Inc..
“each of David Domzalski, VYNE’s President and Chief Executive Officer, Iain Stuart, Ph.D., VYNE’s Chief Scientific Officer, and Mutya Harsch, VYNE’s Chief Legal Officer and General Counsel, resigned as executive officers at the Closing and their employment was terminated effective July 27, 2026”
David Domzalski resigned as President and Chief Executive Officer at VYNE Therapeutics Inc..
“each of David Domzalski, VYNE’s President and Chief Executive Officer, Iain Stuart, Ph.D., VYNE’s Chief Scientific Officer, and Mutya Harsch, VYNE’s Chief Legal Officer and General Counsel, resigned as executive officers at the Closing and their employment was terminated effective July 27, 2026”
VYNE Therapeutics Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“March 11, 2026, the Company received a letter (the “Extension Notice”) from Nasdaq notifying the Company that its request for an extension to regain compliance with the minimum bid price requirement has been granted, and the Company has an additional 180 calendar days, or until September 7, 2026, to regain compliance with the minimum bid price requirement. Nasdaq’s determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of t”
VYNE Therapeutics Inc. amended Amendment to Agreement and Plan of Merger and Reorganization with Yarrow Merger Sub Corp. and Yarrow Bioscience, Inc. (effective 2026-01-30).
“On January 30, 2026, VYNE Therapeutics Inc., a Delaware corporation (“VYNE”), Yarrow Merger Sub Corp., a Delaware corporation and a wholly-owned subsidiary of VYNE (“Merger Sub”), and Yarrow Bioscience, Inc., a Delaware corporation (“Yarrow”), entered into an amendment (the “Amendment”) to that certain Agreement and Plan of Merger and Reorganization, dated December 17, 2025 (as amended, the “Merger Agreement”), by and among VYNE, Merger Sub and Yarrow.”
VYNE Therapeutics Inc. entered into Agreement and Plan of Merger and Reorganization with Yarrow Bioscience, Inc., a Delaware corporation, and Yellow Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of the Company (effective 2025-12-17).
“On December 17, 2025, VYNE Therapeutics Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Yarrow Bioscience, Inc., a Delaware corporation (“Yarrow”), and Yellow Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”)”
VYNE Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“September 11, 2025, VYNE Therapeutics Inc. (the “Company”) received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company’s common stock (the “Common Stock”) was below $1.00 per share for 30 consecutive business days. The notification does not impact the listing of the Company’s Common Stock on the Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)”
VYNE Therapeutics Inc. reported the quarter ended March 31, 2024 results: revenue $0.1 million, net income $6.2 million, EPS $0.15.
“financial statements included in VYNE’s Quarterly Report on Form 10-Q filed today for additional discussion on liquidity and capital resources. Revenues. Revenues totaled $0.1 million for each of the three months ended March 31, 2024 and 2023, consisting of royalty revenue from the Company's royalty agreement with LEO Pharma, to whom VYNE previously licensed”
VYNE Therapeutics Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
“VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.”
Christine Borowski was appointed as Director at VYNE Therapeutics Inc..
“On December 29, 2023, the Board appointed Dr. Christine Borowski to serve as a Class II director of the Company, effective as of January 1, 2024”
VYNE Therapeutics Inc. shareholders approved Approval of the 2023 Plan at the 2023-12-13 meeting.
“Proposal 3 . The stockholders approved the 2023 Plan. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 9,650,797 204,128 7,253 945,627”
VYNE Therapeutics Inc. shareholders approved Ratification of appointment of Baker Tilly US, LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-12-13 meeting.
“Proposal 2 . The stockholders ratified the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 10,666,683 113,944 27,178 0”
VYNE Therapeutics Inc. shareholders approved Election of director Sharon Barbari at the 2023-12-13 meeting.
“Proposal 1 . The stockholders elected the following director to the Board, to hold office until the 2026 annual meeting of stockholders or until her successor is elected. The voting results were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Sharon Barbari 9,678,059 184,119 945,627”
VYNE Therapeutics Inc. reported financial results for the three and nine months ended September 30, 2023.
“On November 13, 2023, VYNE Therapeutics Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023.”
VYNE Therapeutics Inc. terminated Purchase Agreement with Lincoln Park Capital Fund, LLC (effective 2023-10-30).
“On October 30, 2023, the Company delivered a notice of termination to Lincoln Park terminating the Purchase Agreement effective as of one business day following delivery of notice.”
VYNE Therapeutics Inc. entered into Securities Purchase Agreement with certain institutional and other accredited investors valued at $88.2 million (effective 2023-10-27).
“On October 27, 2023, VYNE Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional and other accredited investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement transaction”
VYNE Therapeutics Inc. reported the three and six months ended June 30, 2023 results: net income Net loss and net loss per share for the quarter ended June 30, 2023 was $10.1 million and $3.09.
“VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and six months ended June 30, 2023 and provided a business update.”
VYNE Therapeutics Inc. reported the three months ended March 31, 2023 results: net income $ (5,622).
“1 Financial Performance (in thousands) Three Months Ended March 31 2023 2022 Loss from continuing operations (GAAP) $ (5,612) $ (8,694) Adjusted loss from continuing operations (non-GAAP)* $ (4,756) $ (7,449) Net (loss) income (GAAP) $ (5,622) $ 4,670 Adjusted net (loss) income (non-GAAP)* $ (4,766) $ 5,563 *See "”
VYNE Therapeutics Inc. entered into License Agreement with Tay Therapeutics Limited (formerly known as In4Derm Limited, “Tay”) valued at up to an aggregate of $43.75 million (effective 2023-04-28).
“On April 28, 2023, VYNE Therapeutics Inc. (the “Company”) and Tay Therapeutics Limited (formerly known as In4Derm Limited, “Tay”) entered into a License Agreement (the “License Agreement”)”
VYNE Therapeutics Inc. reported financial results for year ended December 31, 2022.
“On March 9, 2023, VYNE Therapeutics Inc. issued a press release announcing its financial results for the year ended December 31, 2022.”
VYNE Therapeutics Inc. amended Letter Agreement with Tay Therapeutics Limited valued at $250,000 (effective 2023-02-27).
“the parties entered into a Letter Agreement on February 27, 2023 (the “Letter Agreement”) to extend the Option Term to April 30, 2023. Pursuant to the terms of the Letter Agreement, VYNE has agreed to pay Tay a non-refundable fee in the amount of $250,000 to extend the Option Term.”
VYNE Therapeutics Inc.: Effected a one-for-eighteen reverse stock split of common stock via Certificate of Amendment to Amended and Restated Certificate of Incorporation (effective 2023-02-10).
“On February 10, 2023, VYNE Therapeutics Inc. (the “Company”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”) to effect a one-for-eighteen (1:18) reverse stock split of its outstanding common stock, effective as of February 10, 2023 (the “Reverse Stock Split”).”
VYNE Therapeutics Inc.: Filed a Certificate of Elimination to remove the designation of Series A Convertible Preferred Stock from the Amended and Restated Certificate of Incorporation, making those shares authorized but unissued preferred stock (effective 2023-01-17).
“On January 17, 2023, the Company filed a Certificate of Elimination (the “Certificate”) with the Secretary of State of the State of Delaware with respect to the Series A Preferred Stock. The Certificate (i) eliminated the previous designation of 3,000 shares of Series A Preferred Stock from the Company’s Amended and Restated Certificate of Incorporation, none of which were outstanding at the time of filing, and (ii) caused such shares of Series A Preferred Stock to resume their status as authorized but unissued and non-designated shares of preferred stock.”
VYNE Therapeutics Inc. shareholders approved Adjournment Proposal at the 2023-01-12 meeting.
“With respect to the shares of Common Stock present in person or by proxy at the Special Meeting, votes “For” were 24,029,283; votes “Against” were 3,693,414; votes abstaining or withheld were 423,246, and there were no broker non-votes. Including the votes of the Series A Preferred, voting results were as follows: Votes For Votes Against Abstentions / Withheld 2,624,348,039 403,374,658 423,246 The Adjournment Proposal was approved.”
VYNE Therapeutics Inc. shareholders approved Reverse Stock Split Proposal at the 2023-01-12 meeting.
“With respect to the shares of Common Stock present in person or by proxy at the Special Meeting, votes “For” were 24,230,441; votes “Against” were 3,711,239; votes abstaining or withheld were 204,263, and there were no broker non-votes. Including the votes of the Series A Preferred, voting results were as follows: Votes For Votes Against Abstentions / Withheld 2,625,767,750 402,173,930 204,263 The Reverse Stock Split Proposal was approved.”
VYNE Therapeutics Inc. reported three and nine months ended September 30, 2022 results: net income Net loss (GAAP) $ (9,459 ) $ (21,285 ) $ (13,265 ) $ (61,759 ).
“VYNE Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.”
Tyler Zeronda was named as Chief Financial Officer and Treasurer at VYNE Therapeutics Inc..
“On March 14, 2022, the Company named Tyler Zeronda as the Chief Financial Officer and Treasurer of the Company effective immediately.”
Rex Bright departed as Director at VYNE Therapeutics Inc..
“The Company deeply regrets to announce that Mr. Rex Bright passed away on January 11, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.